Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.08
-0.36 (-1.95%)
Mar 3, 2026, 4:00 PM EST - Market closed
Takeda Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 4,517,900 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 | 3,197,812 | |
Revenue Growth (YoY) | -5.56% | 7.45% | 5.87% | 12.85% | 11.61% | -2.84% |
Cost of Revenue | 1,550,600 | 1,580,217 | 1,426,878 | 1,244,072 | 1,106,846 | 994,308 |
Gross Profit | 2,967,300 | 3,001,334 | 2,836,884 | 2,783,406 | 2,462,160 | 2,203,504 |
Selling, General & Admin | 1,048,100 | 1,130,736 | 1,080,619 | 997,999 | 886,361 | 875,663 |
Depreciation & Amortization Expenses | 947,093 | 543,233 | 652,117 | 542,443 | 472,915 | 421,864 |
Research & Development | 624,500 | 730,232 | 729,021 | 633,322 | 526,087 | 455,833 |
Other Operating Expenses | 77,400 | 180,521 | 187,148 | 119,823 | 115,952 | -59,125 |
Total Operating Expenses | 2,697,093 | 2,584,722 | 2,648,905 | 2,293,587 | 2,001,315 | 1,694,235 |
Operating Income | 607,000 | 342,580 | 187,979 | 489,819 | 460,844 | 509,269 |
Interest Income | 279,800 | 46,549 | 52,093 | 62,913 | 23,700 | 105,521 |
Interest Expense | 421,100 | 210,065 | 219,850 | 169,698 | 166,607 | 248,631 |
Other Non-Operating Income (Expense) | -4,915 | -3,986 | 6,473 | -8,630 | -15,367 | 76 |
Total Non-Operating Income (Expense) | 697,785 | 252,628 | 278,416 | 223,981 | 174,940 | 354,228 |
Pretax Income | 463,300 | 175,078 | 26,795 | 374,404 | 302,571 | 366,235 |
Provision for Income Taxes | -92,654 | -66,941 | 91,440 | -57,050 | -72,405 | 9,936 |
Net Income | 340,391 | 107,828 | 144,067 | 317,017 | 230,059 | 376,005 |
Minority Interest in Earnings | -92 | 315 | 130 | 21 | 107 | 166 |
Net Income to Common | 340,391 | 107,828 | 144,067 | 317,017 | 230,059 | 376,005 |
Net Income Growth | -11.88% | -25.15% | -54.55% | 37.80% | -38.81% | 749.90% |
Shares Outstanding (Basic) | 3,159 | 3,155 | 3,129 | 3,104 | 3,127 | 3,124 |
Shares Outstanding (Diluted) | 3,159 | 3,208 | 3,161 | 3,140 | 3,154 | 3,147 |
Shares Change (YoY) | 0.31% | 1.49% | 0.67% | -0.46% | 0.23% | 0.47% |
EPS (Basic) | 107.75 | 34.18 | 46.05 | 102.14 | 73.57 | 120.36 |
EPS (Diluted) | 107.75 | 33.62 | 45.58 | 100.97 | 72.94 | 119.48 |
EPS Growth | 18.56% | -26.25% | -54.86% | 38.44% | -38.96% | 745.88% |
Free Cash Flow | - | 856,387 | 540,924 | 836,499 | 999,853 | 899,725 |
Free Cash Flow Growth | - | 58.32% | -35.34% | -16.34% | 11.13% | 65.80% |
Free Cash Flow Per Share | - | - | - | 266.42 | 316.98 | 285.89 |
Dividends Per Share | 198.000 | 196.000 | 188.000 | 180.000 | 180.000 | 180.000 |
Dividend Growth | 1.02% | 4.25% | 4.44% | - | - | - |
Gross Margin | 65.68% | 65.51% | 66.53% | 69.11% | 68.99% | 68.91% |
Operating Margin | 13.44% | 7.48% | 4.41% | 12.16% | 12.91% | 15.93% |
Profit Margin | 7.54% | 2.36% | 3.38% | 7.87% | 6.45% | 11.76% |
FCF Margin | - | 18.69% | 12.69% | 20.77% | 28.01% | 28.14% |
EBITDA | 607,000 | 1,210,505 | 1,065,998 | 1,218,613 | 1,098,510 | 1,094,392 |
EBITDA Margin | 13.44% | 26.42% | 25.00% | 30.26% | 30.78% | 34.22% |
EBIT | 607,000 | 342,580 | 187,979 | 489,819 | 460,844 | 509,269 |
EBIT Margin | 13.44% | 7.48% | 4.41% | 12.16% | 12.91% | 15.93% |
Effective Tax Rate | -20.00% | -38.23% | 341.26% | -15.24% | -23.93% | 2.71% |
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.